<DOC>
	<DOCNO>NCT01177943</DOCNO>
	<brief_summary>To demonstrate bioequivalence 12.5 milliliter ( mL ) atomoxetine oral solution ( 4 milligram per milliliter [ mg/mL ] ) compare 2 capsule atomoxetine ( 25 mg per capsule ) healthy adult male Japanese subject .</brief_summary>
	<brief_title>A Bioequivalence ( BE ) Study Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria Are healthy Japanese male , determine medical history physical examination Have body mass index ( BMI ) great equal 17.6 less equal 26.4 kg/m2 screen Cytochrome P450 2D6 ( CYP2D6 ) genotype categorize extensive metabolizers ( EM ) result screen test . EM include Intermediate Metabolizer ( IM ) Ultrarapid Metabolizer ( UM ) . Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Are reliable willing make available duration study willing follow study procedure Have give write informed consent approve Lilly ethical review board govern site trial activity Exclusion Criteria Are investigator site personnel directly affiliate study immediate family . Immediate family define spouse , parent , child sibling , whether biological legally adopt . Persons employ sponsor ( , employee , temporary contract worker , designees responsible conduct study ) . Are currently enrol , discontinue within last 4 month , clinical trial involve investigational drug device , concurrently enrol type medical research judge scientifically medically compatible study . Have know allergy atomoxetine ( LY139603 ) relate compound . Are person ever use atomoxetine , previously participate study study investigate atomoxetine receive study drug . An abnormality 12lead ECG opinion investigator increase risk participate study , correct QT ( QTc ) interval &gt; 450 millisecond ( msec ) . Subjects current past history clinically significant elevate blood pressure ( Supine systolic blood pressure great equal 140 millimeter mercury [ mmHg ] Supine diastolic blood pressure great equal 90 mmHg ) Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism elimination drug constitute risk take study medication interfere interpretation data . Regularly use know drug abuse , show positive finding urinary drug screening . Have positive result Human Immunodeficiency Virus ( HIV ) test , show evidence possible infection . Have positive result hepatitis B antigen test , show evidence possible infection . Have positive result hepatitis C antibody test , show evidence possible infection . Have positive result syphilis test , show evidence possible infection . Use intend use overthecounter prescription medication 7 14 day , respectively prior dosing . Blood donation 200 mL blood component blood donation within one month prior dose , donate 400 mL blood within 3 month prior dose , history blood donation 950 mL within last 12 month . Have average weekly alcohol intake exceed 21 unit per week unwilling stop alcohol consumption duration study ( 1 unit = 360 mL beer ; 150 mL wine ; 45 mL distil spirit ) . Subjects history seizure , exclude febrile convulsion childhood . Exposure monoamine oxidase inhibitor ( MAOI ) drug herbal preparation central nervous system effect St. John 's Wort within last 2 week prior dose . Subjects history presence narrowangle glaucoma . Have history presence significant neuropsychiatric disease ( example , maniacdepressive illness , schizophrenia , depression ) . Currently smoke excess 10 cigarette per day , equivalent tobacco nicotine substitute , unwilling stop smoking duration specify protocol Subjects determine investigator sponsor inadequate inclusion study reason .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>